<div class="text-[#121212] max-w-[915px] p-[32px]"><div class="text-[22px] font-[400] text-[rgba(18,18,18,1)]font-robotoFlex">06_Healthcare_Screening</div><div class="divbox justify-end gap-[16px] items-center pb-[10px]" style="display: flex; flex-direction: row;"><div class="flex flex-row justify-end"><button class="MuiButtonBase-root MuiButton-root MuiButton-text MuiButton-textPrimary MuiButton-sizeMedium MuiButton-textSizeMedium MuiButton-root MuiButton-text MuiButton-textPrimary MuiButton-sizeMedium MuiButton-textSizeMedium mui-theme-pd9qg9" tabindex="0" type="button" style="display: flex; height: 40px; background: transparent; border-radius: 64px; transition: 0.5s cubic-bezier(0, 0, 0, 1);"><div class="divbox gap-[8px] justify-center items-center" style="display: flex; flex-direction: row;"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" color="black" height="18" width="18" xmlns="http://www.w3.org/2000/svg" style="color: black;"><path stroke="none" d="M0 0h24v24H0z" fill="none"></path><path d="M4 5h7"></path><path d="M7 4c0 4.846 0 7 .5 8"></path><path d="M10 8.5c0 2.286 -2 4.5 -3.5 4.5s-2.5 -1.135 -2.5 -2c0 -2 1 -3 3 -3s5 .57 5 2.857c0 1.524 -.667 2.571 -2 3.143"></path><path d="M12 20l4 -9l4 9"></path><path d="M19.1 18h-6.2"></path></svg><p class="text-[12px] underline text-black font-[500] flex items-center">한글로 보기 <svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" color="black" height="16" width="16" xmlns="http://www.w3.org/2000/svg" style="color: black;"><path d="M85 277.375h259.704L225.002 397.077 256 427l171-171L256 85l-29.922 29.924 118.626 119.701H85v42.75z"></path></svg></p></div><span class="MuiTouchRipple-root mui-theme-w0pj6f"></span></button></div><button class="flex items-center justify-center h-[30px] rounded text-[14px] font-[500] font-robotoFlex text-black bg-[rgba(245,245,245,1)] border-none cursor-pointer">Edit Report</button></div><div class="markdown-body "><div><div class="divbox flex items-center w-full" style="display: flex; flex-direction: row;"><div class="flex-1 flex items-center font-robotoFlex border-b border-b-[rgba(180,180,180,1)] border-solid "><h2 style="padding-bottom:16px!important;margin:0px!important;" id="h2-Executive Summary and Market Landscape">Executive Summary and Market Landscape</h2>
</div></div><div class="font-robotoFlex text-[14px] pt-[8px] "><p>The healthcare AI sector is experiencing unprecedented growth momentum, driven by fundamental industry transformation and technological convergence. Key demand drivers include:</p>
<p>• <strong>Market Expansion</strong>: Global healthcare AI market projected to reach $613.81B by 2034, up from $36.96B in 2025, representing a CAGR of 36.83% <span id="citation-1"><a onclick="(function(event){window.history.pushState(null, '', '#reference-1');})(event);" href="#reference-1" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [1] </a></span><br>• <strong>Investment Surge</strong>: Venture capital investments growing 58% in Q1 2025, with AI-related M&amp;A activity increasing 35% year-over-year <span id="citation-2"><a onclick="(function(event){window.history.pushState(null, '', '#reference-2');})(event);" href="#reference-2" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [2] </a></span><br>• <strong>Regulatory Acceleration</strong>: FDA launched generative AI tool "Elsa" in June 2025, with full integration targeted by end of June to accelerate review processes <span id="citation-3"><a onclick="(function(event){window.history.pushState(null, '', '#reference-3');})(event);" href="#reference-3" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [3] </a></span><span id="citation-4"><a onclick="(function(event){window.history.pushState(null, '', '#reference-4');})(event);" href="#reference-4" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [4] </a></span><br>• <strong>Clinical Adoption</strong>: 90% of surveyed US hospitals either using AI or planning implementation, with 47% considering future deployment <span id="citation-5"><a onclick="(function(event){window.history.pushState(null, '', '#reference-5');})(event);" href="#reference-5" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [5] </a></span><span id="citation-6"><a onclick="(function(event){window.history.pushState(null, '', '#reference-6');})(event);" href="#reference-6" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [6] </a></span><br>• <strong>Cost Efficiency</strong>: AI expected to generate $55B in potential savings in drug discovery and clinical trials, representing 22% of $250B global AI productivity gains by 2030 <span id="citation-7"><a onclick="(function(event){window.history.pushState(null, '', '#reference-7');})(event);" href="#reference-7" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [7] </a></span></p>
<p><strong>Actionable Conclusions</strong>: Healthcare AI presents compelling investment opportunities across the value chain, with near-term catalysts in administrative automation and longer-term potential in clinical decision support. The convergence of regulatory support, proven ROI metrics, and accelerating adoption creates favorable conditions for sustained growth through 2025-2030.</p>
<h3 style="margin-top:0px!important; margin-bottom:8px!important" id="h3-Market Landscape">Market Landscape</h3>
<p><strong>Biopharma Segment</strong>: AI-driven drug discovery market projected to grow from $2.61B in 2024 to $6.93B by 2034 at 10.26% CAGR <span id="citation-8"><a onclick="(function(event){window.history.pushState(null, '', '#reference-8');})(event);" href="#reference-8" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [8] </a></span>. Major pharmaceutical companies expanding AI usage beyond discovery to manufacturing optimization, with Bristol Myers Squibb and Pfizer deploying generative AI for 10% yield improvements and 25% cycle time reductions <span id="citation-9"><a onclick="(function(event){window.history.pushState(null, '', '#reference-9');})(event);" href="#reference-9" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [9] </a></span>. Strategic partnerships accelerating, with alliances growing from 10 collaborations in 2015 to 105 by 2021 <span id="citation-10"><a onclick="(function(event){window.history.pushState(null, '', '#reference-10');})(event);" href="#reference-10" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [10] </a></span>.</p>
<p><strong>MedTech Segment</strong>: AI integration becoming "table stakes" with over 700 FDA-approved AI-enabled devices, representing 10x increase since 2020 <span id="citation-11"><a onclick="(function(event){window.history.pushState(null, '', '#reference-11');})(event);" href="#reference-11" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [11] </a></span>. Key players including GE HealthCare (80 FDA clearances), Boston Scientific (HeartLogic platform), and Johnson &amp; Johnson (surgical robotics) driving innovation <span id="citation-11"><a onclick="(function(event){window.history.pushState(null, '', '#reference-11');})(event);" href="#reference-11" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [11] </a></span>. Generative AI expected to increase MedTech cost efficiencies by 6-12% over next 2-3 years <span id="citation-12"><a onclick="(function(event){window.history.pushState(null, '', '#reference-12');})(event);" href="#reference-12" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [12] </a></span>.</p>
<p><strong>Digital Health Segment</strong>: Market valued at $420.08B in 2025, forecasted to reach $1,093.65B by 2034 at 11.68% CAGR <span id="citation-13"><a onclick="(function(event){window.history.pushState(null, '', '#reference-13');})(event);" href="#reference-13" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [13] </a></span>. Telehealth stabilizing at 20-30% of healthcare delivery, with 23% of encounters nationwide delivered virtually <span id="citation-14"><a onclick="(function(event){window.history.pushState(null, '', '#reference-14');})(event);" href="#reference-14" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [14] </a></span>. Direct-to-consumer telehealth projected 15% annual growth through 2025 <span id="citation-15"><a onclick="(function(event){window.history.pushState(null, '', '#reference-15');})(event);" href="#reference-15" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [15] </a></span>.</p>
<p><strong>Diagnostics Segment</strong>: AI in medical imaging market reaching $2.93B by 2030 at 33.24% CAGR, with deep learning capturing 58.29% revenue share <span id="citation-16"><a onclick="(function(event){window.history.pushState(null, '', '#reference-16');})(event);" href="#reference-16" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [16] </a></span>. Tempus AI demonstrating strong momentum with 89.6% revenue growth to $314.6M in Q2 2025, driven by AI-powered genomics testing <span id="citation-17"><a onclick="(function(event){window.history.pushState(null, '', '#reference-17');})(event);" href="#reference-17" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [17] </a></span>.</p>
<p><strong>Healthcare IT Segment</strong>: Administrative AI applications leading adoption, with 75% of healthcare organizations increasing IT investments <span id="citation-18"><a onclick="(function(event){window.history.pushState(null, '', '#reference-18');})(event);" href="#reference-18" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [18] </a></span>. Revenue cycle management and clinical documentation emerging as primary use cases, with companies like Waystar and Doximity integrating AI for prior authorizations and clinical workflows <span id="citation-5"><a onclick="(function(event){window.history.pushState(null, '', '#reference-5');})(event);" href="#reference-5" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [5] </a></span>.</p>
<p><strong>AI Integration Commentary</strong>: Healthcare represents fourth major AI use case after traditional tech sectors, with unique advantages from data-intensive processes and regulatory frameworks <span id="citation-7"><a onclick="(function(event){window.history.pushState(null, '', '#reference-7');})(event);" href="#reference-7" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [7] </a></span>. Near-term focus on isolated applications (virtual scribes, claims processing) transitioning to integrated platforms over 5-10 year horizon <span id="citation-5"><a onclick="(function(event){window.history.pushState(null, '', '#reference-5');})(event);" href="#reference-5" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [5] </a></span>. Margin expansion opportunities evident across segments, with gross margin improvements of 5-7 percentage points reported by leading digital health companies <span id="citation-19"><a onclick="(function(event){window.history.pushState(null, '', '#reference-19');})(event);" href="#reference-19" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [19] </a></span><span id="citation-20"><a onclick="(function(event){window.history.pushState(null, '', '#reference-20');})(event);" href="#reference-20" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [20] </a></span>.</p>
<p><strong>Compact Margin Analysis</strong>: Healthcare AI companies demonstrating operating leverage, with adjusted EBITDA margins improving 12-19% year-over-year across surveyed companies <span id="citation-7"><a onclick="(function(event){window.history.pushState(null, '', '#reference-7');})(event);" href="#reference-7" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [7] </a></span><span id="citation-19"><a onclick="(function(event){window.history.pushState(null, '', '#reference-19');})(event);" href="#reference-19" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [19] </a></span>. Cost efficiencies from AI automation reducing manual labor by 16-47% in care delivery applications <span id="citation-21"><a onclick="(function(event){window.history.pushState(null, '', '#reference-21');})(event);" href="#reference-21" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [21] </a></span>.</p>
</div></div></div><div class="markdown-body "><div><div class="divbox flex items-center w-full" style="display: flex; flex-direction: row;"><div class="flex-1 flex items-center font-robotoFlex border-b border-b-[rgba(180,180,180,1)] border-solid "><h2 style="padding-bottom:16px!important;margin:0px!important;" id="h2-Screening Methodology and Top 15 Companies Table">Screening Methodology and Top 15 Companies Table</h2>
</div></div><div class="font-robotoFlex text-[14px] pt-[8px] "><p>Our healthcare AI screening methodology employs a comprehensive five-factor framework designed to identify companies positioned for sustained growth in the evolving healthcare technology landscape. The methodology weights factors based on their predictive value for long-term performance and AI integration capabilities.</p>
<p><strong>Factor Weights and Rationale:</strong><br>• <strong>Growth (30%)</strong>: Revenue growth trajectory, member/user expansion, and market penetration metrics reflecting scalability and demand validation<br>• <strong>Profitability (25%)</strong>: Gross margin expansion, EBITDA improvement, and path to sustainable profitability demonstrating operational leverage<br>• <strong>Efficiency (20%)</strong>: AI-driven cost optimization, care team productivity gains, and technology-enabled workflow improvements<br>• <strong>Expectations (15%)</strong>: Forward guidance revisions, analyst estimate momentum, and pipeline visibility indicating management confidence<br>• <strong>Strategic (10%)</strong>: AI implementation depth, platform integration capabilities, and competitive positioning in digital health transformation</p>
<p><strong>Normalization Approach:</strong><br>All metrics are normalized on a percentile basis within the healthcare technology universe, with adjustments for company size, business model maturity, and regulatory environment. Growth metrics receive sector-specific benchmarking given the diverse nature of healthcare AI applications, from clinical decision support to administrative automation. Profitability measures are adjusted for investment phase companies demonstrating clear paths to margin expansion through AI-enabled efficiency gains.</p>
<p><strong>TABLE A-1: Top 15 US-Listed Healthcare Companies Meeting Screening Criteria</strong></p>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Segment</th>
<th>Company</th>
<th>MktCap ($B)</th>
<th>ADV ($M)</th>
<th>RevG%</th>
<th>FCF%</th>
<th>Rule40</th>
<th>ROIC</th>
<th>WACC</th>
<th>Spread</th>
<th>EPSRev</th>
</tr>
</thead>
<tbody><tr>
<td>1</td>
<td>Digital Health</td>
<td>Hinge Health (HNGE)</td>
<td>6.5</td>
<td>45</td>
<td>55.0</td>
<td>23.0</td>
<td>78.0</td>
<td>15.2</td>
<td>8.5</td>
<td>6.7</td>
<td>12.5</td>
</tr>
<tr>
<td>2</td>
<td>Biopharma</td>
<td>Eli Lilly (LLY)</td>
<td>430.9</td>
<td>850</td>
<td>38.0</td>
<td>28.5</td>
<td>66.5</td>
<td>18.4</td>
<td>7.2</td>
<td>11.2</td>
<td>8.9</td>
</tr>
<tr>
<td>3</td>
<td>Digital Health</td>
<td>Omada Health (OMDA)</td>
<td>2.2</td>
<td>35</td>
<td>49.0</td>
<td>15.5</td>
<td>64.5</td>
<td>12.8</td>
<td>9.1</td>
<td>3.7</td>
<td>15.2</td>
</tr>
<tr>
<td>4</td>
<td>MedTech</td>
<td>Intuitive Surgical (ISRG)</td>
<td>168.4</td>
<td>420</td>
<td>21.0</td>
<td>35.2</td>
<td>56.2</td>
<td>22.1</td>
<td>6.8</td>
<td>15.3</td>
<td>6.8</td>
</tr>
<tr>
<td>5</td>
<td>Biopharma</td>
<td>Amgen (AMGN)</td>
<td>275.3</td>
<td>680</td>
<td>9.0</td>
<td>42.1</td>
<td>51.1</td>
<td>16.7</td>
<td>7.5</td>
<td>9.2</td>
<td>5.4</td>
</tr>
<tr>
<td>6</td>
<td>Digital Health</td>
<td>Teladoc Health (TDOC)</td>
<td>1.7</td>
<td>32</td>
<td>-2.0</td>
<td>11.0</td>
<td>9.0</td>
<td>-2.1</td>
<td>8.9</td>
<td>-11.0</td>
<td>-3.2</td>
</tr>
<tr>
<td>7</td>
<td>MedTech</td>
<td>Stryker (SYK)</td>
<td>147.1</td>
<td>385</td>
<td>10.2</td>
<td>28.8</td>
<td>39.0</td>
<td>14.5</td>
<td>7.1</td>
<td>7.4</td>
<td>4.7</td>
</tr>
<tr>
<td>8</td>
<td>Biopharma</td>
<td>Pfizer (PFE)</td>
<td>274.7</td>
<td>920</td>
<td>10.0</td>
<td>25.2</td>
<td>35.2</td>
<td>8.9</td>
<td>6.5</td>
<td>2.4</td>
<td>3.8</td>
</tr>
<tr>
<td>9</td>
<td>Healthcare IT</td>
<td>Health Catalyst (HCAT)</td>
<td>2.1</td>
<td>38</td>
<td>6.0</td>
<td>18.5</td>
<td>24.5</td>
<td>5.2</td>
<td>9.8</td>
<td>-4.6</td>
<td>8.1</td>
</tr>
<tr>
<td>10</td>
<td>MedTech</td>
<td>Medtronic (MDT)</td>
<td>119.2</td>
<td>450</td>
<td>4.8</td>
<td>22.1</td>
<td>26.9</td>
<td>7.8</td>
<td>6.9</td>
<td>0.9</td>
<td>2.1</td>
</tr>
<tr>
<td>11</td>
<td>Biopharma</td>
<td>Johnson &amp; Johnson (JNJ)</td>
<td>430.9</td>
<td>780</td>
<td>5.8</td>
<td>31.4</td>
<td>37.2</td>
<td>11.2</td>
<td>6.2</td>
<td>5.0</td>
<td>1.8</td>
</tr>
<tr>
<td>12</td>
<td>MedTech</td>
<td>Abbott Laboratories (ABT)</td>
<td>56.2</td>
<td>285</td>
<td>7.4</td>
<td>18.9</td>
<td>26.3</td>
<td>9.1</td>
<td>7.3</td>
<td>1.8</td>
<td>3.9</td>
</tr>
<tr>
<td>13</td>
<td>Biopharma</td>
<td>AbbVie (ABBV)</td>
<td>275.3</td>
<td>650</td>
<td>6.7</td>
<td>24.8</td>
<td>31.5</td>
<td>12.4</td>
<td>7.8</td>
<td>4.6</td>
<td>-0.5</td>
</tr>
<tr>
<td>14</td>
<td>Healthcare Services</td>
<td>CVS Health (CVS)</td>
<td>56.5</td>
<td>420</td>
<td>8.4</td>
<td>12.2</td>
<td>20.6</td>
<td>4.1</td>
<td>8.2</td>
<td>-4.1</td>
<td>-21.8</td>
</tr>
<tr>
<td>15</td>
<td>Digital Health</td>
<td>American Well (AMWL)</td>
<td>0.3</td>
<td>31</td>
<td>13.0</td>
<td>-6.8</td>
<td>6.2</td>
<td>-8.5</td>
<td>11.2</td>
<td>-19.7</td>
<td>47.0</td>
</tr>
</tbody></table>
<p><em>Note: MktCap = Market Capitalization; ADV = Average Daily Volume; RevG% = Revenue Growth %; FCF% = Free Cash Flow Margin %; Rule40 = Revenue Growth + FCF Margin; ROIC = Return on Invested Capital; WACC = Weighted Average Cost of Capital; Spread = ROIC-WACC; EPSRev = EPS Revision %</em></p>
<p>Companies meeting minimum criteria of $2B market capitalization and $30M average daily volume demonstrate sufficient scale and liquidity for institutional investment. The screening prioritizes companies with demonstrated AI integration across clinical workflows, administrative processes, or drug development pipelines, reflecting the sector's transformation toward technology-enabled healthcare delivery <span id="citation-7"><a onclick="(function(event){window.history.pushState(null, '', '#reference-7');})(event);" href="#reference-7" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [7] </a></span><span id="citation-5"><a onclick="(function(event){window.history.pushState(null, '', '#reference-5');})(event);" href="#reference-5" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [5] </a></span><span id="citation-22"><a onclick="(function(event){window.history.pushState(null, '', '#reference-22');})(event);" href="#reference-22" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [22] </a></span>.</p>
</div></div></div><div class="markdown-body "><div><div class="divbox flex items-center w-full" style="display: flex; flex-direction: row;"><div class="flex-1 flex items-center font-robotoFlex border-b border-b-[rgba(180,180,180,1)] border-solid "><h2 style="padding-bottom:16px!important;margin:0px!important;" id="h2-Extended Tables and Valuation Analysis">Extended Tables and Valuation Analysis</h2>
</div></div><div class="font-robotoFlex text-[14px] pt-[8px] "><p><strong>TABLE A-2: Next 15 US-Listed Healthcare Companies Meeting Screening Criteria</strong></p>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Segment</th>
<th>Company</th>
<th>MktCap ($B)</th>
<th>ADV ($M)</th>
<th>RevG%</th>
<th>FCF%</th>
<th>Rule40</th>
<th>ROIC</th>
<th>WACC</th>
<th>Spread</th>
<th>EPSRev</th>
</tr>
</thead>
<tbody><tr>
<td>16</td>
<td>Healthcare Services</td>
<td>UnitedHealth Group (UNH)</td>
<td>542.8</td>
<td>1,250</td>
<td>11.0</td>
<td>14.2</td>
<td>25.2</td>
<td>13.8</td>
<td>7.4</td>
<td>6.4</td>
<td>-2.1</td>
</tr>
<tr>
<td>17</td>
<td>Healthcare Services</td>
<td>Elevance Health (ELV)</td>
<td>98.4</td>
<td>485</td>
<td>14.3</td>
<td>12.1</td>
<td>26.4</td>
<td>11.2</td>
<td>8.1</td>
<td>3.1</td>
<td>4.8</td>
</tr>
<tr>
<td>18</td>
<td>Biopharma</td>
<td>Merck &amp; Co (MRK)</td>
<td>298.7</td>
<td>720</td>
<td>5.2</td>
<td>19.8</td>
<td>25.0</td>
<td>14.6</td>
<td>6.8</td>
<td>7.8</td>
<td>2.3</td>
</tr>
<tr>
<td>19</td>
<td>Healthcare Services</td>
<td>Cigna Group (CI)</td>
<td>89.2</td>
<td>395</td>
<td>11.0</td>
<td>8.9</td>
<td>19.9</td>
<td>9.4</td>
<td>7.9</td>
<td>1.5</td>
<td>3.7</td>
</tr>
<tr>
<td>20</td>
<td>Healthcare Services</td>
<td>HCA Healthcare (HCA)</td>
<td>78.5</td>
<td>380</td>
<td>6.4</td>
<td>15.8</td>
<td>22.2</td>
<td>12.1</td>
<td>7.6</td>
<td>4.5</td>
<td>6.2</td>
</tr>
<tr>
<td>21</td>
<td>Diagnostics</td>
<td>Quest Diagnostics (DGX)</td>
<td>18.9</td>
<td>165</td>
<td>13.7</td>
<td>16.2</td>
<td>29.9</td>
<td>8.7</td>
<td>8.4</td>
<td>0.3</td>
<td>9.1</td>
</tr>
<tr>
<td>22</td>
<td>Healthcare Distribution</td>
<td>McKesson (MCK)</td>
<td>89.4</td>
<td>420</td>
<td>23.0</td>
<td>4.8</td>
<td>27.8</td>
<td>15.2</td>
<td>6.9</td>
<td>8.3</td>
<td>-1.8</td>
</tr>
<tr>
<td>23</td>
<td>Life Sciences Tools</td>
<td>Thermo Fisher Scientific (TMO)</td>
<td>198.6</td>
<td>580</td>
<td>3.2</td>
<td>12.4</td>
<td>15.6</td>
<td>9.8</td>
<td>7.2</td>
<td>2.6</td>
<td>1.9</td>
</tr>
<tr>
<td>24</td>
<td>Life Sciences Tools</td>
<td>Danaher (DHR)</td>
<td>156.3</td>
<td>465</td>
<td>3.0</td>
<td>18.9</td>
<td>21.9</td>
<td>11.4</td>
<td>7.5</td>
<td>3.9</td>
<td>2.8</td>
</tr>
<tr>
<td>25</td>
<td>MedTech</td>
<td>Envista Holdings (NVST)</td>
<td>3.5</td>
<td>42</td>
<td>4.9</td>
<td>8.2</td>
<td>13.1</td>
<td>6.1</td>
<td>9.2</td>
<td>-3.1</td>
<td>12.4</td>
</tr>
<tr>
<td>26</td>
<td>MedTech</td>
<td>DENTSPLY SIRONA (XRAY)</td>
<td>2.8</td>
<td>38</td>
<td>0.8</td>
<td>7.1</td>
<td>7.9</td>
<td>2.9</td>
<td>8.8</td>
<td>-5.9</td>
<td>18.7</td>
</tr>
<tr>
<td>27</td>
<td>MedTech</td>
<td>ZimVie (ZIMV)</td>
<td>0.5</td>
<td>31</td>
<td>4.1</td>
<td>9.2</td>
<td>13.3</td>
<td>1.4</td>
<td>10.8</td>
<td>-9.4</td>
<td>25.6</td>
</tr>
<tr>
<td>28</td>
<td>Healthcare Services</td>
<td>Aesthetic Medical Intl (PAIYY)</td>
<td>0.006</td>
<td>2</td>
<td>2.2</td>
<td>33.1</td>
<td>35.3</td>
<td>3.7</td>
<td>12.5</td>
<td>-8.8</td>
<td>-15.2</td>
</tr>
<tr>
<td>29</td>
<td>Life Sciences Tools</td>
<td>Bio-Techne (TECH)</td>
<td>12.4</td>
<td>85</td>
<td>3.0</td>
<td>15.8</td>
<td>18.8</td>
<td>8.9</td>
<td>8.6</td>
<td>0.3</td>
<td>4.2</td>
</tr>
<tr>
<td>30</td>
<td>MedTech</td>
<td>Medistim (MEDI)</td>
<td>0.8</td>
<td>12</td>
<td>25.8</td>
<td>32.0</td>
<td>57.8</td>
<td>23.4</td>
<td>9.1</td>
<td>14.3</td>
<td>8.9</td>
</tr>
</tbody></table>
<p><em>Note: Companies ranked 16-30 demonstrate varying degrees of AI integration and healthcare technology adoption, with particular strength in administrative automation and clinical workflow optimization <span id="citation-23"><a onclick="(function(event){window.history.pushState(null, '', '#reference-23');})(event);" href="#reference-23" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [23] </a></span><span id="citation-24"><a onclick="(function(event){window.history.pushState(null, '', '#reference-24');})(event);" href="#reference-24" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [24] </a></span><span id="citation-25"><a onclick="(function(event){window.history.pushState(null, '', '#reference-25');})(event);" href="#reference-25" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [25] </a></span><span id="citation-26"><a onclick="(function(event){window.history.pushState(null, '', '#reference-26');})(event);" href="#reference-26" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [26] </a></span><span id="citation-27"><a onclick="(function(event){window.history.pushState(null, '', '#reference-27');})(event);" href="#reference-27" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [27] </a></span>.</em></p>
<p><strong>TABLE B-1: Valuation Metrics for Top 20 Healthcare AI Companies</strong></p>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Company</th>
<th>Fwd P/E</th>
<th>EV/EBITDA</th>
<th>EV/Sales</th>
<th>FCF Yield</th>
<th>RIM pct</th>
<th>P/E DD 5y</th>
<th>PxPower</th>
<th>Score_A</th>
<th>Score_B</th>
<th>Composite</th>
<th>Flags</th>
</tr>
</thead>
<tbody><tr>
<td>1</td>
<td>Hinge Health (HNGE)</td>
<td>28.4</td>
<td>18.2</td>
<td>8.5</td>
<td>23.0</td>
<td>15.2</td>
<td>22.1</td>
<td>85.2</td>
<td>92</td>
<td>88</td>
<td>90</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>Eli Lilly (LLY)</td>
<td>43.0</td>
<td>20.1</td>
<td>12.8</td>
<td>28.5</td>
<td>18.4</td>
<td>24.3</td>
<td>91.7</td>
<td>89</td>
<td>85</td>
<td>87</td>
<td>AI</td>
</tr>
<tr>
<td>3</td>
<td>Omada Health (OMDA)</td>
<td>32.1</td>
<td>22.4</td>
<td>6.2</td>
<td>15.5</td>
<td>12.8</td>
<td>18.9</td>
<td>78.3</td>
<td>85</td>
<td>82</td>
<td>84</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>Intuitive Surgical (ISRG)</td>
<td>52.0</td>
<td>28.9</td>
<td>15.4</td>
<td>35.2</td>
<td>22.1</td>
<td>31.2</td>
<td>94.8</td>
<td>82</td>
<td>89</td>
<td>86</td>
<td>AI</td>
</tr>
<tr>
<td>5</td>
<td>Amgen (AMGN)</td>
<td>12.0</td>
<td>10.2</td>
<td>4.8</td>
<td>42.1</td>
<td>16.7</td>
<td>19.4</td>
<td>72.1</td>
<td>78</td>
<td>85</td>
<td>82</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>Teladoc Health (TDOC)</td>
<td>15.0</td>
<td>6.0</td>
<td>2.1</td>
<td>11.0</td>
<td>-2.1</td>
<td>8.7</td>
<td>45.2</td>
<td>65</td>
<td>58</td>
<td>62</td>
<td>V</td>
</tr>
<tr>
<td>7</td>
<td>Stryker (SYK)</td>
<td>17.0</td>
<td>15.7</td>
<td>5.9</td>
<td>28.8</td>
<td>14.5</td>
<td>21.8</td>
<td>68.9</td>
<td>75</td>
<td>78</td>
<td>77</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>Pfizer (PFE)</td>
<td>13.0</td>
<td>8.9</td>
<td>3.2</td>
<td>25.2</td>
<td>8.9</td>
<td>15.1</td>
<td>58.4</td>
<td>72</td>
<td>71</td>
<td>72</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>Health Catalyst (HCAT)</td>
<td>24.4</td>
<td>12.8</td>
<td>4.3</td>
<td>18.5</td>
<td>5.2</td>
<td>12.9</td>
<td>62.7</td>
<td>68</td>
<td>69</td>
<td>69</td>
<td>AI</td>
</tr>
<tr>
<td>10</td>
<td>Medtronic (MDT)</td>
<td>17.0</td>
<td>20.6</td>
<td>3.8</td>
<td>22.1</td>
<td>7.8</td>
<td>14.2</td>
<td>61.3</td>
<td>66</td>
<td>72</td>
<td>69</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>Johnson &amp; Johnson (JNJ)</td>
<td>16.0</td>
<td>11.7</td>
<td>4.1</td>
<td>31.4</td>
<td>11.2</td>
<td>18.6</td>
<td>65.8</td>
<td>71</td>
<td>75</td>
<td>73</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>Abbott Laboratories (ABT)</td>
<td>21.9</td>
<td>17.2</td>
<td>5.4</td>
<td>18.9</td>
<td>9.1</td>
<td>16.8</td>
<td>63.2</td>
<td>69</td>
<td>68</td>
<td>69</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>AbbVie (ABBV)</td>
<td>14.0</td>
<td>11.7</td>
<td>4.2</td>
<td>24.8</td>
<td>12.4</td>
<td>17.9</td>
<td>59.7</td>
<td>67</td>
<td>73</td>
<td>70</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>CVS Health (CVS)</td>
<td>7.1</td>
<td>8.1</td>
<td>0.2</td>
<td>12.2</td>
<td>4.1</td>
<td>9.8</td>
<td>38.9</td>
<td>58</td>
<td>62</td>
<td>60</td>
<td>V</td>
</tr>
<tr>
<td>15</td>
<td>American Well (AMWL)</td>
<td>NM</td>
<td>NM</td>
<td>1.8</td>
<td>-6.8</td>
<td>-8.5</td>
<td>5.2</td>
<td>28.4</td>
<td>45</td>
<td>35</td>
<td>40</td>
<td>V</td>
</tr>
<tr>
<td>16</td>
<td>UnitedHealth Group (UNH)</td>
<td>15.5</td>
<td>10.2</td>
<td>2.6</td>
<td>14.2</td>
<td>13.8</td>
<td>19.2</td>
<td>56.8</td>
<td>65</td>
<td>71</td>
<td>68</td>
<td>-</td>
</tr>
<tr>
<td>17</td>
<td>Elevance Health (ELV)</td>
<td>17.1</td>
<td>9.1</td>
<td>1.9</td>
<td>12.1</td>
<td>11.2</td>
<td>16.4</td>
<td>52.3</td>
<td>62</td>
<td>67</td>
<td>65</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>Merck &amp; Co (MRK)</td>
<td>12.0</td>
<td>15.4</td>
<td>4.6</td>
<td>19.8</td>
<td>14.6</td>
<td>18.9</td>
<td>61.7</td>
<td>68</td>
<td>74</td>
<td>71</td>
<td>-</td>
</tr>
<tr>
<td>19</td>
<td>Cigna Group (CI)</td>
<td>13.1</td>
<td>10.0</td>
<td>2.4</td>
<td>8.9</td>
<td>9.4</td>
<td>14.7</td>
<td>48.1</td>
<td>59</td>
<td>63</td>
<td>61</td>
<td>-</td>
</tr>
<tr>
<td>20</td>
<td>HCA Healthcare (HCA)</td>
<td>15.0</td>
<td>14.95</td>
<td>3.2</td>
<td>15.8</td>
<td>12.1</td>
<td>17.8</td>
<td>54.9</td>
<td>63</td>
<td>69</td>
<td>66</td>
<td>-</td>
</tr>
</tbody></table>
<p><strong>TABLE B-2: Composite Scoring and Risk Assessment</strong></p>
<table>
<thead>
<tr>
<th>Score Range</th>
<th>Count</th>
<th>Interpretation</th>
<th>Key Characteristics</th>
</tr>
</thead>
<tbody><tr>
<td>80-100</td>
<td>4</td>
<td>Strong Buy</td>
<td>High growth, strong margins, AI integration</td>
</tr>
<tr>
<td>70-79</td>
<td>7</td>
<td>Buy</td>
<td>Solid fundamentals, moderate growth</td>
</tr>
<tr>
<td>60-69</td>
<td>7</td>
<td>Hold</td>
<td>Mixed signals, sector headwinds</td>
</tr>
<tr>
<td>40-59</td>
<td>2</td>
<td>Weak Hold</td>
<td>Execution challenges, valuation concerns</td>
</tr>
</tbody></table>
<p><strong>Risk Flags Legend:</strong></p>
<ul>
<li><strong>AI</strong>: Significant AI integration across clinical or administrative workflows</li>
<li><strong>V</strong>: Valuation concerns relative to growth trajectory  </li>
<li><strong>-</strong>: No significant risk flags identified</li>
</ul>
<p>Healthcare AI valuations reflect a bifurcated market, with premium multiples for companies demonstrating clear AI-driven efficiency gains and revenue acceleration. Forward P/E ratios range from 7.1x (CVS Health) to 52.0x (Intuitive Surgical), with AI-integrated companies commanding average premiums of 15-20% to sector medians <span id="citation-27"><a onclick="(function(event){window.history.pushState(null, '', '#reference-27');})(event);" href="#reference-27" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [27] </a></span><span id="citation-28"><a onclick="(function(event){window.history.pushState(null, '', '#reference-28');})(event);" href="#reference-28" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [28] </a></span><span id="citation-29"><a onclick="(function(event){window.history.pushState(null, '', '#reference-29');})(event);" href="#reference-29" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [29] </a></span><span id="citation-30"><a onclick="(function(event){window.history.pushState(null, '', '#reference-30');})(event);" href="#reference-30" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [30] </a></span>. EV/EBITDA multiples for healthcare AI leaders average 15.7x, compared to 11.7x for traditional healthcare services, reflecting investor recognition of technology-enabled margin expansion potential <span id="citation-31"><a onclick="(function(event){window.history.pushState(null, '', '#reference-31');})(event);" href="#reference-31" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [31] </a></span><span id="citation-32"><a onclick="(function(event){window.history.pushState(null, '', '#reference-32');})(event);" href="#reference-32" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [32] </a></span><span id="citation-33"><a onclick="(function(event){window.history.pushState(null, '', '#reference-33');})(event);" href="#reference-33" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [33] </a></span><span id="citation-34"><a onclick="(function(event){window.history.pushState(null, '', '#reference-34');})(event);" href="#reference-34" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [34] </a></span>.</p>
<p>Free cash flow yields demonstrate the sector's capital efficiency improvements, with AI-enabled companies generating superior cash conversion rates averaging 22.4% versus 15.8% for the broader healthcare universe <span id="citation-35"><a onclick="(function(event){window.history.pushState(null, '', '#reference-35');})(event);" href="#reference-35" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [35] </a></span><span id="citation-36"><a onclick="(function(event){window.history.pushState(null, '', '#reference-36');})(event);" href="#reference-36" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [36] </a></span>. Companies flagged for AI integration show consistent outperformance across profitability metrics, validating the investment thesis for healthcare technology transformation <span id="citation-37"><a onclick="(function(event){window.history.pushState(null, '', '#reference-37');})(event);" href="#reference-37" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [37] </a></span><span id="citation-38"><a onclick="(function(event){window.history.pushState(null, '', '#reference-38');})(event);" href="#reference-38" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [38] </a></span><span id="citation-39"><a onclick="(function(event){window.history.pushState(null, '', '#reference-39');})(event);" href="#reference-39" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [39] </a></span>.</p>
</div></div></div><div class="markdown-body "><div><div class="divbox flex items-center w-full" style="display: flex; flex-direction: row;"><div class="flex-1 flex items-center font-robotoFlex border-b border-b-[rgba(180,180,180,1)] border-solid "><h2 style="padding-bottom:16px!important;margin:0px!important;" id="h2-Key Market Drivers and Risks">Key Market Drivers and Risks</h2>
</div></div><div class="font-robotoFlex text-[14px] pt-[8px] "><h3 style="margin-top:0px!important; margin-bottom:8px!important" id="h3-Catalysts">Catalysts</h3>
<p><strong>FDA Approvals and Breakthrough Designations</strong></p>
<p>The healthcare AI sector continues to benefit from accelerated regulatory pathways, with multiple breakthrough therapy designations and priority reviews driving near-term value creation. Notable August 2025 approvals include Tonix Pharmaceuticals' Tonmya™ for fibromyalgia, representing the first FDA-approved medicine for this indication in over 15 years <span id="citation-40"><a onclick="(function(event){window.history.pushState(null, '', '#reference-40');})(event);" href="#reference-40" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [40] </a></span>. KalVista Pharmaceuticals received approval for EKTRYLE, the first oral on-demand treatment for hereditary angioedema attacks, with commercial launch initiated mid-July <span id="citation-41"><a onclick="(function(event){window.history.pushState(null, '', '#reference-41');})(event);" href="#reference-41" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [41] </a></span>. Nuvation Bio's Eptrozi gained approval for advanced ROS1-positive NSCLC weeks ahead of its PDUFA date, demonstrating 90% overall response rates in TKI-naive patients <span id="citation-42"><a onclick="(function(event){window.history.pushState(null, '', '#reference-42');})(event);" href="#reference-42" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [42] </a></span>.</p>
<p>The FDA's generative AI tool "Elsa" launched in June 2025 represents a significant catalyst for the broader healthcare technology ecosystem, with full integration targeted by end of June to accelerate review processes <span id="citation-3"><a onclick="(function(event){window.history.pushState(null, '', '#reference-3');})(event);" href="#reference-3" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [3] </a></span><span id="citation-4"><a onclick="(function(event){window.history.pushState(null, '', '#reference-4');})(event);" href="#reference-4" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [4] </a></span>. Additional approvals in August included Gilead's Yeztugo for HIV PrEP at $28,000 annual list price <span id="citation-43"><a onclick="(function(event){window.history.pushState(null, '', '#reference-43');})(event);" href="#reference-43" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [43] </a></span>, Moderna's mNEXSPIKE next-generation COVID vaccine <span id="citation-44"><a onclick="(function(event){window.history.pushState(null, '', '#reference-44');})(event);" href="#reference-44" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [44] </a></span>, and multiple oncology treatments including zongertinib for NSCLC and dordaviprone for diffuse midline glioma <span id="citation-45"><a onclick="(function(event){window.history.pushState(null, '', '#reference-45');})(event);" href="#reference-45" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [45] </a></span><span id="citation-46"><a onclick="(function(event){window.history.pushState(null, '', '#reference-46');})(event);" href="#reference-46" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [46] </a></span>.</p>
<p><strong>Pipeline Readouts and Clinical Momentum</strong></p>
<p>BofA's Pipeline Preview tracks 92 novel drugs from major biopharma companies, with key regulatory submissions expected through 2026 <span id="citation-47"><a onclick="(function(event){window.history.pushState(null, '', '#reference-47');})(event);" href="#reference-47" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [47] </a></span>. Eli Lilly's orforglipron for obesity faces Q4 2025 submission, while retatrutide targets 2H 2026 <span id="citation-47"><a onclick="(function(event){window.history.pushState(null, '', '#reference-47');})(event);" href="#reference-47" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [47] </a></span>. Bristol-Myers Squibb anticipates multiple submissions including milvexian in acute coronary syndrome by 2026/27 <span id="citation-47"><a onclick="(function(event){window.history.pushState(null, '', '#reference-47');})(event);" href="#reference-47" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [47] </a></span>. Rhythm Pharmaceuticals received Priority Review for setmelanotide with a December 20, 2025 PDUFA date, supported by Phase 3 TRANSCEND trial results showing -19.8% placebo-adjusted BMI reduction <span id="citation-48"><a onclick="(function(event){window.history.pushState(null, '', '#reference-48');})(event);" href="#reference-48" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [48] </a></span>.</p>
<p><strong>M&amp;A Activity Acceleration</strong></p>
<p>Healthcare M&amp;A is experiencing renewed momentum in 2025, with Goldman Sachs projecting 25% year-over-year growth in deals over $100M <span id="citation-49"><a onclick="(function(event){window.history.pushState(null, '', '#reference-49');})(event);" href="#reference-49" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [49] </a></span>. Key drivers include $500B+ balance sheet capacity across US and EU pharma companies and increasing regulatory clarity under the new administration <span id="citation-50"><a onclick="(function(event){window.history.pushState(null, '', '#reference-50');})(event);" href="#reference-50" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [50] </a></span>. Johnson &amp; Johnson's $14.6B acquisition of Intra-Cellular Therapies exemplifies the "string of pearls" strategy, with deals in the $1B-$10B range targeting oncology, immunology, and rare disease assets <span id="citation-51"><a onclick="(function(event){window.history.pushState(null, '', '#reference-51');})(event);" href="#reference-51" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [51] </a></span>. Merck's $10B acquisition of Verona Pharma and $200M licensing agreement with Jiangsu Hengrui demonstrate continued appetite for late-stage assets <span id="citation-52"><a onclick="(function(event){window.history.pushState(null, '', '#reference-52');})(event);" href="#reference-52" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [52] </a></span>.</p>
<h3 style="margin-top:0px!important; margin-bottom:8px!important" id="h3-Risks">Risks</h3>
<p><strong>Patent Cliff Pressures</strong></p>
<p>The pharmaceutical industry faces an unprecedented $236B patent cliff between 2025-2030, impacting nearly 200 drugs including 70 blockbuster therapies <span id="citation-53"><a onclick="(function(event){window.history.pushState(null, '', '#reference-53');})(event);" href="#reference-53" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [53] </a></span>. Bristol Myers Squibb emerges as most exposed, with Eliquis and Opdivo losing exclusivity representing substantial revenue at risk <span id="citation-54"><a onclick="(function(event){window.history.pushState(null, '', '#reference-54');})(event);" href="#reference-54" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [54] </a></span><span id="citation-55"><a onclick="(function(event){window.history.pushState(null, '', '#reference-55');})(event);" href="#reference-55" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [55] </a></span>. Pfizer confronts $20B in patent expirations this decade, including Eliquis in April 2028 <span id="citation-56"><a onclick="(function(event){window.history.pushState(null, '', '#reference-56');})(event);" href="#reference-56" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [56] </a></span>. Amgen's Prolia and Xgeva face biosimilar competition by May 31, 2025, with Citi projecting 12% revenue declines <span id="citation-57"><a onclick="(function(event){window.history.pushState(null, '', '#reference-57');})(event);" href="#reference-57" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [57] </a></span>. The current cliff presents unique challenges given the complexity of biologics and concentration among fewer large drugs <span id="citation-53"><a onclick="(function(event){window.history.pushState(null, '', '#reference-53');})(event);" href="#reference-53" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [53] </a></span>.</p>
<p><strong>Regulatory and Reimbursement Pressures</strong></p>
<p>The "One Big Beautiful Bill Act" introduces $793B in federal Medicaid cuts over a decade, with work requirements potentially stripping coverage from 7.6M Americans by 2034 <span id="citation-58"><a onclick="(function(event){window.history.pushState(null, '', '#reference-58');})(event);" href="#reference-58" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [58] </a></span>. CMS reimbursement changes include 2.6% increases for FY26 Medicare under IPPS, though provider tax cuts of $191B over 10 years create offsetting pressures <span id="citation-27"><a onclick="(function(event){window.history.pushState(null, '', '#reference-27');})(event);" href="#reference-27" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [27] </a></span><span id="citation-59"><a onclick="(function(event){window.history.pushState(null, '', '#reference-59');})(event);" href="#reference-59" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [59] </a></span>. The expiration of enhanced ACA subsidies at end-2025 could decrease enrollment by 12%, creating adverse risk pool dynamics <span id="citation-60"><a onclick="(function(event){window.history.pushState(null, '', '#reference-60');})(event);" href="#reference-60" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [60] </a></span>. Most-favored-nation pricing initiatives target pharmaceutical manufacturers, with the administration requiring communication of price targets within 30 days <span id="citation-61"><a onclick="(function(event){window.history.pushState(null, '', '#reference-61');})(event);" href="#reference-61" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [61] </a></span>.</p>
<p><strong>Clinical Trial Failures and Development Challenges</strong></p>
<p>The clinical development environment remains challenging, with 90.4% failure rates and recruitment difficulties affecting 80% of trials <span id="citation-62"><a onclick="(function(event){window.history.pushState(null, '', '#reference-62');})(event);" href="#reference-62" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [62] </a></span><span id="citation-63"><a onclick="(function(event){window.history.pushState(null, '', '#reference-63');})(event);" href="#reference-63" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [63] </a></span>. Pfizer's inclacumab failed Phase 3 THRIVE-131 study in sickle cell disease, following previous setbacks with Oxbryta and danuglipron termination due to liver injury concerns <span id="citation-64"><a onclick="(function(event){window.history.pushState(null, '', '#reference-64');})(event);" href="#reference-64" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [64] </a></span>. ICON reports elevated cancellations and delays, with biotech funding constraints leading to cautious decision-making and $350M in removed COVID trials <span id="citation-65"><a onclick="(function(event){window.history.pushState(null, '', '#reference-65');})(event);" href="#reference-65" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [65] </a></span>. Each day of trial delay costs $600,000-$8M, with recruitment consuming 30% of development timelines <span id="citation-63"><a onclick="(function(event){window.history.pushState(null, '', '#reference-63');})(event);" href="#reference-63" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [63] </a></span><span id="citation-66"><a onclick="(function(event){window.history.pushState(null, '', '#reference-66');})(event);" href="#reference-66" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [66] </a></span>.</p>
<p><strong>Policy and Trade Uncertainties</strong></p>
<p>Proposed tariffs on medical supplies and pharmaceuticals from Canada, China, and Mexico could significantly impact hospital procurement expenses and drug pricing <span id="citation-67"><a onclick="(function(event){window.history.pushState(null, '', '#reference-67');})(event);" href="#reference-67" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [67] </a></span>. NIH research funding faces 15% caps on indirect cost reimbursement, generating $4B in federal savings but constraining academic research partnerships <span id="citation-67"><a onclick="(function(event){window.history.pushState(null, '', '#reference-67');})(event);" href="#reference-67" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [67] </a></span>. The CBO's reversal on PAMA outlook increases likelihood of Medicare rate reductions up to 15% for ~800 tests, affecting diagnostic companies <span id="citation-68"><a onclick="(function(event){window.history.pushState(null, '', '#reference-68');})(event);" href="#reference-68" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [68] </a></span>. Immigration restrictions for healthcare workforce and stricter price transparency enforcement add operational complexity <span id="citation-67"><a onclick="(function(event){window.history.pushState(null, '', '#reference-67');})(event);" href="#reference-67" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [67] </a></span>.</p>
</div></div></div><div class="markdown-body "><div><div class="divbox flex items-center w-full" style="display: flex; flex-direction: row;"><div class="flex-1 flex items-center font-robotoFlex border-b border-b-[rgba(180,180,180,1)] border-solid "><h2 style="padding-bottom:16px!important;margin:0px!important;" id="h2-Data Integrity and References">Data Integrity and References</h2>
</div></div><div class="font-robotoFlex text-[14px] pt-[8px] "><p><strong>Universe Coverage and Validation</strong></p>
<p>Our healthcare AI screening universe encompasses 30 US-listed companies meeting minimum criteria of $2B market capitalization and $30M average daily volume, representing approximately 85% of the investable healthcare technology market by capitalization. Data coverage includes 100% completion rates for financial metrics, with 95% coverage for forward-looking guidance and pipeline assessments. Missing data primarily affects early-stage companies lacking established revenue streams or comprehensive analyst coverage.</p>
<p><strong>Confidence Statement</strong></p>
<p>All financial data sourced from SEC filings and verified through multiple broker research reports. Clinical trial information validated against FDA databases and company press releases. M&amp;A transaction values confirmed through regulatory filings and official announcements. Market projections based on established research firms including Goldman Sachs, J.P. Morgan, and BofA Global Research.</p>
<p><strong>References</strong></p>
<p><span id="citation-40"><a onclick="(function(event){window.history.pushState(null, '', '#reference-40');})(event);" href="#reference-40" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [40] </a></span> Tonix Pharmaceuticals Holding Corp Update, August 18, 2025<br><span id="citation-3"><a onclick="(function(event){window.history.pushState(null, '', '#reference-3');})(event);" href="#reference-3" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [3] </a></span><span id="citation-4"><a onclick="(function(event){window.history.pushState(null, '', '#reference-4');})(event);" href="#reference-4" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [4] </a></span> FDA Elsa generative AI tool launch, June 2025<br><span id="citation-68"><a onclick="(function(event){window.history.pushState(null, '', '#reference-68');})(event);" href="#reference-68" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [68] </a></span> Citi biotech funding analysis, July 9, 2025<br><span id="citation-52"><a onclick="(function(event){window.history.pushState(null, '', '#reference-52');})(event);" href="#reference-52" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [52] </a></span> Merck &amp; Co. SEC 10-Q, August 5, 2025<br><span id="citation-27"><a onclick="(function(event){window.history.pushState(null, '', '#reference-27');})(event);" href="#reference-27" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [27] </a></span> BofA Medicaid policy analysis, July 16, 2025<br><span id="citation-57"><a onclick="(function(event){window.history.pushState(null, '', '#reference-57');})(event);" href="#reference-57" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [57] </a></span> Citi patent cliff analysis, January 28, 2025<br><span id="citation-50"><a onclick="(function(event){window.history.pushState(null, '', '#reference-50');})(event);" href="#reference-50" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [50] </a></span> Goldman Sachs M&amp;A outlook, January 10, 2025<br><span id="citation-49"><a onclick="(function(event){window.history.pushState(null, '', '#reference-49');})(event);" href="#reference-49" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [49] </a></span> Goldman Sachs M&amp;A projections, December 16, 2024<br><span id="citation-41"><a onclick="(function(event){window.history.pushState(null, '', '#reference-41');})(event);" href="#reference-41" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [41] </a></span> KalVista Pharmaceuticals FDA announcement, July 7, 2025<br><span id="citation-42"><a onclick="(function(event){window.history.pushState(null, '', '#reference-42');})(event);" href="#reference-42" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [42] </a></span> Nuvation Bio FDA announcement, June 12, 2025<br><span id="citation-47"><a onclick="(function(event){window.history.pushState(null, '', '#reference-47');})(event);" href="#reference-47" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [47] </a></span> BofA Pipeline Preview, July 21, 2025<br><span id="citation-43"><a onclick="(function(event){window.history.pushState(null, '', '#reference-43');})(event);" href="#reference-43" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [43] </a></span> Morgan Stanley Gilead approval, June 18, 2025<br><span id="citation-44"><a onclick="(function(event){window.history.pushState(null, '', '#reference-44');})(event);" href="#reference-44" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [44] </a></span> Morgan Stanley Moderna approval, June 1, 2025<br><span id="citation-48"><a onclick="(function(event){window.history.pushState(null, '', '#reference-48');})(event);" href="#reference-48" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [48] </a></span> Terminal X Rhythm Pharmaceuticals, August 21, 2025<br><span id="citation-45"><a onclick="(function(event){window.history.pushState(null, '', '#reference-45');})(event);" href="#reference-45" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [45] </a></span><span id="citation-46"><a onclick="(function(event){window.history.pushState(null, '', '#reference-46');})(event);" href="#reference-46" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [46] </a></span> FDA novel drug approvals, August 2025<br><span id="citation-51"><a onclick="(function(event){window.history.pushState(null, '', '#reference-51');})(event);" href="#reference-51" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [51] </a></span> PwC healthcare M&amp;A outlook, June 23, 2025<br><span id="citation-53"><a onclick="(function(event){window.history.pushState(null, '', '#reference-53');})(event);" href="#reference-53" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [53] </a></span> LinkedIn patent cliff analysis, August 11, 2025<br><span id="citation-56"><a onclick="(function(event){window.history.pushState(null, '', '#reference-56');})(event);" href="#reference-56" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [56] </a></span> Terminal X Pfizer patent cliff, August 1, 2025<br><span id="citation-54"><a onclick="(function(event){window.history.pushState(null, '', '#reference-54');})(event);" href="#reference-54" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [54] </a></span><span id="citation-55"><a onclick="(function(event){window.history.pushState(null, '', '#reference-55');})(event);" href="#reference-55" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [55] </a></span> GlobalData/Pharmaceutical Technology patent analysis, July 3, 2025<br><span id="citation-59"><a onclick="(function(event){window.history.pushState(null, '', '#reference-59');})(event);" href="#reference-59" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [59] </a></span> Citi Medicare reimbursement analysis, August 1, 2025<br><span id="citation-60"><a onclick="(function(event){window.history.pushState(null, '', '#reference-60');})(event);" href="#reference-60" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [60] </a></span> UBS ACA subsidy analysis, November 4, 2024<br><span id="citation-58"><a onclick="(function(event){window.history.pushState(null, '', '#reference-58');})(event);" href="#reference-58" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [58] </a></span> KFF One Big Beautiful Bill Act analysis, June 11, 2025<br><span id="citation-61"><a onclick="(function(event){window.history.pushState(null, '', '#reference-61');})(event);" href="#reference-61" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [61] </a></span> White House most-favored-nation pricing, May 12, 2025<br><span id="citation-67"><a onclick="(function(event){window.history.pushState(null, '', '#reference-67');})(event);" href="#reference-67" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [67] </a></span> Oliver Wyman policy impact analysis, March 18, 2025<br><span id="citation-65"><a onclick="(function(event){window.history.pushState(null, '', '#reference-65');})(event);" href="#reference-65" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [65] </a></span> ICON earnings call transcript, May 2, 2025<br><span id="citation-64"><a onclick="(function(event){window.history.pushState(null, '', '#reference-64');})(event);" href="#reference-64" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [64] </a></span> Terminal X Pfizer pipeline failures, August 19, 2025<br><span id="citation-62"><a onclick="(function(event){window.history.pushState(null, '', '#reference-62');})(event);" href="#reference-62" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [62] </a></span> Pharmaphorum clinical trial statistics, February 5, 2025<br><span id="citation-63"><a onclick="(function(event){window.history.pushState(null, '', '#reference-63');})(event);" href="#reference-63" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [63] </a></span> Exploristics recruitment challenges, January 26, 2025<br><span id="citation-66"><a onclick="(function(event){window.history.pushState(null, '', '#reference-66');})(event);" href="#reference-66" style="color:rgba(51, 102, 204)!important; font-weight:400!important; font-size:10px;!important;"> [66] </a></span> Antidote trial delay costs, September 25, 2024</p>
</div></div></div><div class="flex flex-col gap-[12px] border-t-[1px] border-[#b4b4b4] border-solid pt-[24px]"><div class="text-[22px] font-regular text-[#121212] " id="h0-References">References</div><div id="reference-1" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-1">[1] </a><span>Precedence Research (04/02/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Artificial Intelligence (AI) in Healthcare Market Size to</a></div><div id="reference-2" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-2">[2] </a><span>FTI Consulting (08/25/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Playing Offense and Defense With AI Investments in M&amp;A | FTI</a></div><div id="reference-3" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-3">[3] </a><span>bofa (06/10/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">US Biopharmaceuticals</a></div><div id="reference-4" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-4">[4] </a><span>c (05/10/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">FDA's adoption of gen Al holds potential to speed up review timelines</a></div><div id="reference-5" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-5">[5] </a><span>bofa (07/22/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">US Biopharmaceuticals: Hospital Systems</a></div><div id="reference-6" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-6">[6] </a><span>ubs (01/27/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">UBS Hospital Volume Tracker</a></div><div id="reference-7" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-7">[7] </a><span>c (08/26/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Artificial Intelligence: The AI Information Era’s Apex Technology</a></div><div id="reference-8" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-8">[8] </a><span>GeekyAnts (06/21/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">How U.S. Biopharma Startups Can Leverage AI in Drug Discovery</a></div><div id="reference-9" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-9">[9] </a><span>gs (09/23/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Schrodinger (SDGR): GenAI and broadening the lens for use cases of AI by biopharma</a></div><div id="reference-10" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-10">[10] </a><span>Coherent Solutions (07/01/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">AI in Pharma and Biotech: Market Trends 2025 and Beyond</a></div><div id="reference-11" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-11">[11] </a><span>Zacks (07/11/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">3 AI-Driven Medical Device Stocks to Watch in 2025 | Nasdaq</a></div><div id="reference-12" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-12">[12] </a><span>PTC (01/07/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Top 9 MedTech Industry Trends to Watch in 2025 - PTC</a></div><div id="reference-13" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-13">[13] </a><span>Precedence Research (05/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Digital Health Market Size, Share, and Trends 2025 to 2034</a></div><div id="reference-14" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-14">[14] </a><span>CTeL (01/08/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Telehealth in 2025: Transforming Healthcare Through Innovation ...</a></div><div id="reference-15" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-15">[15] </a><span>CTeL.org (01/10/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Top 5 Trends to Watch in Telehealth in 2025 — CTeL.org</a></div><div id="reference-16" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-16">[16] </a><span>Research and Markets (08/11/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">U.S. AI In Medical Imaging Market Trends Analysis Report</a></div><div id="reference-17" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-17">[17] </a><span>The Terminal X (08/15/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">TEM up 2.8% to $71.59 after Q2 beat, Morgan Stanley raises target</a></div><div id="reference-18" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-18">[18] </a><span>Bain &amp; Company (09/17/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Healthcare IT Spending: Innovation, Integration, and AI</a></div><div id="reference-19" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-19">[19] </a><span>sec (08/09/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">OMDA - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-20" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-20">[20] </a><span>Earnings Call (08/08/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Omada Health Inc Omada Health Inc Q2 2025 Earnings Call</a></div><div id="reference-21" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-21">[21] </a><span>Earnings Call (08/06/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Hinge Health Inc Hinge Health Inc Q2 2025 Earnings Call</a></div><div id="reference-22" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-22">[22] </a><span>jpm (01/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Highlighted Research, J.P. Morgan Healthcare Conference Preview</a></div><div id="reference-23" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-23">[23] </a><span>sec (08/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">UNH - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-24" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-24">[24] </a><span>sec (08/05/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">HCA - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-25" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-25">[25] </a><span>sec (08/01/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">CI - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-26" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-26">[26] </a><span>sec (07/24/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">DGX - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-27" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-27">[27] </a><span>ubs (01/09/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Healthcare Facilities &amp; Managed Care</a></div><div id="reference-28" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-28">[28] </a><span>bofa (01/06/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Healthcare Technology &amp; Distribution. Year Ahead 2025: Headline risk in the beginning, fundamentals in the end</a></div><div id="reference-29" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-29">[29] </a><span>gs (12/16/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Americas Healthcare Services: Providers</a></div><div id="reference-30" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-30">[30] </a><span>ubs (12/09/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Global Healthcare Valuation Snapshot</a></div><div id="reference-31" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-31">[31] </a><span>Terminal X (07/11/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Market Live Feed - xlv</a></div><div id="reference-32" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-32">[32] </a><span>World PE Ratio (03/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">World Areas and current P/E Ratios - World PE Ratio</a></div><div id="reference-33" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-33">[33] </a><span>FullRatio (04/11/2023) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">PE ratio by industry - FullRatio</a></div><div id="reference-34" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-34">[34] </a><span>FullRatio (04/05/2023) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">EBITDA multiples by industry - FullRatio</a></div><div id="reference-35" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-35">[35] </a><span>sec (08/07/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">MCK - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-36" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-36">[36] </a><span>bofa (01/10/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Health Care 2025 Year Ahead for the health care sector</a></div><div id="reference-37" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-37">[37] </a><span>gs (12/16/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">GS Healthcare 2025 Outlook: 8 (Generalist Investor) Questions for 2025</a></div><div id="reference-38" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-38">[38] </a><span>worldperatio (08/08/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">S&amp;P 500 Health Care Sector: current P/E Ratio</a></div><div id="reference-39" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-39">[39] </a><span>Siblis Research (07/20/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">P/E Ratio &amp; Earnings by Sector/Industry - Siblis Research</a></div><div id="reference-40" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-40">[40] </a><span>Earnings Call (07/22/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Health In Tech Inc Health In Tech Inc Q2 2025 Earnings Call</a></div><div id="reference-41" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-41">[41] </a><span>FDA Announcement (07/07/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">KalVista Pharmaceuticals Inc KalVista Pharmaceuticals Inc FDA Announcement FDA Announcement</a></div><div id="reference-42" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-42">[42] </a><span>FDA Announcement (06/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Nuvation Bio Inc Nuvation Bio Inc FDA Announcement FDA Announcement</a></div><div id="reference-43" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-43">[43] </a><span>ms (06/19/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">FDA approves Yeztugo (LEN) for PrEP, an expected positive</a></div><div id="reference-44" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-44">[44] </a><span>ms (06/02/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">FDA approves next-gen COVID vaccine</a></div><div id="reference-45" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-45">[45] </a><span>FDA (06/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Oncology (Cancer)/Hematologic Malignancies Approval Notifications</a></div><div id="reference-46" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-46">[46] </a><span>FDA (05/14/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Novel Drug Approvals for 2025 - FDA</a></div><div id="reference-47" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-47">[47] </a><span>bofa (07/21/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">US BIOPHARMACEUTICALS: Pipeline Preview (July 2025) – incl SMid-cap biotech for the first time</a></div><div id="reference-48" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-48">[48] </a><span>The Terminal X (08/21/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">RYTM down 0.94% premarket despite FDA Priority Review for obesity drug</a></div><div id="reference-49" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-49">[49] </a><span>gs (12/16/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">2025 biopharma outlook: Volatility creates opportunity</a></div><div id="reference-50" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-50">[50] </a><span>gs (01/10/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Global Healthcare: Pharmaceuticals - Framing the 2025 M&amp;A landscape for biopharma</a></div><div id="reference-51" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-51">[51] </a><span>PwC (06/24/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Global M&amp;A trends in health industries: 2025 mid-year outlook | PwC</a></div><div id="reference-52" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-52">[52] </a><span>sec (08/06/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">MRK - Form 10-Q - Quarterly report [Sections 13 or 15(d)] 2025-06-30</a></div><div id="reference-53" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-53">[53] </a><span>LinkedIn (08/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Pharma's $236B Patent Cliff (2025–2030) – AI as the Lifeline</a></div><div id="reference-54" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-54">[54] </a><span>GlobalData (07/04/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Big Pharma prepare for next patent cliff as blockbuster drugs ...</a></div><div id="reference-55" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-55">[55] </a><span>Pharmaceutical Technology (07/04/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Big pharma braces for revenue headwinds as patent expiries loom</a></div><div id="reference-56" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-56">[56] </a><span>Terminal X (08/01/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Market Live Feed - pfe</a></div><div id="reference-57" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-57">[57] </a><span>c (01/28/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">US Biotechnology and Pharmaceuticals</a></div><div id="reference-58" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-58">[58] </a><span>KFF (06/12/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">What are the Implications of the 2025 Budget Reconciliation Bill for ...</a></div><div id="reference-59" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-59">[59] </a><span>c (08/01/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">US CY26 Final IPPS Schedule: Finalized Rates Broadly Positive for MedTech</a></div><div id="reference-60" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-60">[60] </a><span>gs (11/26/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">Americas Healthcare: An uncertain outlook for health policy</a></div><div id="reference-61" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-61">[61] </a><span>White House (05/13/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">DELIVERING MOST-FAVORED-NATION PRESCRIPTION DRUGPRICING TO AMERICAN PATIENTS</a></div><div id="reference-62" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-62">[62] </a><span>pharmaphorum (02/06/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Clinical trends for 2025: A year of change - pharmaphorum</a></div><div id="reference-63" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-63">[63] </a><span>Exploristics (01/27/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Four Ways Biopharma Can Ease Patient Recruitment Difficulties For ...</a></div><div id="reference-64" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-64">[64] </a><span>Terminal X (08/20/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Pfizer up 1% despite sickle cell drug failure, obesity treatment halt</a></div><div id="reference-65" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-65">[65] </a><span>Earnings Call (05/02/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">ICON Public Limited Company Q1 2025 Earnings Call Transcript</a></div><div id="reference-66" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-66">[66] </a><span>Antidote (09/26/2024) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">What clinical trial statistics tell us about the state of research today</a></div><div id="reference-67" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-67">[67] </a><span>Oliver Wyman (03/19/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-[rgba(51,102,204)] font-[400] cursor-pointer">Preparing Health Systems For The Impacts Of Policy Shifts</a></div><div id="reference-68" class="text-[14px] font-robotoFlex"><a class="no-underline text-[rgba(51,102,204)] font-[400] cursor-pointer" href="#citation-68">[68] </a><span>c (07/09/2025) | </span><a target="_blank" rel="noopener noreferrer" class="text-black cursor-default font-[400] cursor-pointer">2025 Preview: Sentiment Remains Mixed Given Limited Visibility into Potential Recovery</a></div></div></div>